Most healing peptide guides stop at BPC-157 and TB-500. That covers two early bottlenecks — blood flow and repair-cell movement — while ignoring the cellular energy those repair cells spend. More complex injuries can also stall on chronic inflammation, poor collagen quality, disrupted sleep, and hormonal timing.
The tiered framework here organizes compounds by function — a soft-tissue starter stack, escalation layers for refractory cases, and separate routes for cartilage, bone, nerve, CNS, and conditioning problems. The goal isn't a longer ingredient list. It's a diagnostic approach: identify what's actually stalling your healing, then address that bottleneck specifically.
| At a Glance | |
|---|---|
| Soft-tissue starter | BPC-157 + TB-500 + NAD+ — addresses blood flow, repair-cell movement, and cellular energy. |
| Refractory soft tissue | Add KPV when inflammation keeps cycling; add GHK-Cu when collagen quality is the limiter. |
| Injury-specific routes | ARA-290 (peripheral nerve), VIP (disc/spine context), cartilage/bone/CNS-specific stacks when the tissue is not ordinary soft tissue. |
| Support layers | SS-31 (stalled healing), Selank (stress), DSIP (sleep), Tesamorelin/Sermorelin (GH recovery) — added if needed. |
| Protocol duration | 4–8 weeks for acute injuries, 8–12 weeks for chronic conditions. |
| Results timeline | Reduced pain and improved mobility within 1–2 weeks, structural remodeling at 4–8 weeks, full protocol effects by 8–12 weeks. |
| Key caveat | All multi-peptide protocols are practitioner-derived. No human RCTs exist for any combination. Individual compounds have preclinical support; stacking rationale is mechanistic, not clinical. |
The evidence landscape is uneven. BPC-157 has 36 studies in a 2025 systematic review — 35 preclinical, 1 clinical with 12 patients.¹ TB-4 (thymosin beta-4, the parent molecule most research uses) has roughly 50 preclinical studies and Phase 1 human safety data. Zero human RCTs exist for any multi-peptide combination. Every stacking protocol described here is practitioner-derived, built on mechanistic rationale and clinical observation rather than controlled trials.
BPC-157, TB-500, and KPV all have unsettled US compounding-pathway questions after FDA removed them from Category 2 in April 2026 and scheduled PCAC review. That is access context, not therapeutic approval and not a scientific verdict. For tested athletes, BPC-157 and TB-500 remain prohibited under WADA rules.
Why Injuries Stall: Repair Bottlenecks
An injury that doesn't improve after 4–6 weeks isn't just "slow healing." Something specific is blocking the repair process. Five core bottlenecks explain most soft-tissue stalls. Sleep, growth-hormone timing, and mitochondrial stability are later escalation layers, not automatic starter-stack problems.
1. Poor perfusion — the tissue is starved
Damaged tissue needs blood flow to deliver oxygen, nutrients, and immune cells. When circulation is restricted — common in tendons, ligaments, and avascular joint surfaces — repair stalls at the earliest stage.
Signs: the area stays cold or pale, swelling persists weeks post-injury, improvements from physical therapy don't hold between sessions. BPC-157 signals new blood vessel formation (angiogenesis¹) and helps reopen the circulation the injury response shut down.
2. Cell migration — the repair crew can't organize
Blood flow gets supplies to the area, but repair cells still need to move through the damaged tissue and organize into useful structure. When that migration step is weak, the injury feels less cold but still locked, stiff, or glued down.
Signs: range of motion improves briefly then stalls, fascia feels stuck, stiffness drops slower than pain, or the injury feels alive but not rebuilt. TB-500 is the migration-side bet: it supports the cell-movement side of repair while BPC-157 supports blood flow and local repair tone.²
3. Cellular energy failure — repair cells can't do the work
Tissue repair is metabolically expensive. Repair cells, immune cells, and blood vessel cells all require functional mitochondria producing adequate energy. In damaged tissue, mitochondria are often compromised by oxidative stress.
Signs: healing that starts but plateaus; recurrent setbacks with modest activity; fatigue concentrated around the injury site. NAD+ restores the cellular energy pool. SS-31 is a later layer when the issue is mitochondrial membrane stress and repeated flare after loading.⁴
4. Poor collagen quality — rebuilding with weak material
New tissue forms, but it lacks structural integrity. Collagen fibers are disorganized, cross-linking is insufficient, and the repair tissue doesn't tolerate load. Common in connective tissue injuries where collagen architecture determines function.
Signs: repeated re-injury at the same site, tissue that feels "loose" or unstable, gains that reverse under load. GHK-Cu regulates collagen remodeling enzymes, directing repair toward organized functional tissue rather than scar.⁵
5. Inflammation gating — the switch won't turn off
Some injuries get blood flow and repair cells back online, then keep cycling: better after a session, worse two days later, swelling after moderate activity. The repair program never consolidates because the inflammation switch keeps re-opening.
Signs: recurring swelling after activity, persistent warmth, pain that worsens with rest rather than load. KPV helps keep the inflammation switch from staying on (NF-kB pathway³) without the tissue-weakening tradeoff of corticosteroids.
Later layer: poor sleep quality — the repair window never opens
Growth hormone peaks during deep sleep, driving overnight tissue repair. When sleep architecture is disrupted — fragmented sleep, insufficient deep sleep stages, or difficulty falling asleep during recovery — the body's primary repair window stays closed.
Signs: waking unrefreshed, difficulty reaching or maintaining deep sleep, recovery that stalls despite good daytime compliance with rehab and nutrition. DSIP restores deep sleep architecture directly. Selank addresses the stress and anxiety that fragment sleep in the first place.
Later layer: hormonal mis-timing — recovery signals fire at the wrong time
Even with adequate sleep, growth hormone release can be blunted — cortisol stays elevated through the night, GH pulses are weak or mistimed, and the overnight repair signal never reaches full amplitude.
Signs: slow healing despite decent sleep, compounding fatigue that doesn't match activity level, poor recovery response to rehab. GH secretagogues like tesamorelin or sermorelin restore pulsatile GH release.⁶
These bottlenecks frequently overlap. A tendon injury with poor blood supply often develops chronic inflammation because inadequate circulation prevents immune cell clearance. The starter stack covers blood flow, repair-cell movement, and energy; refractory cases add collagen-quality and inflammation-gating layers.
The Peptide Toolkit: Building Your Protocol
Step 1 — Start with the Core Stack
Start here for ordinary soft-tissue injury: tendon, ligament, muscle, fascia, joint capsule, scar remodeling, or post-procedure tissue support. These three compounds cover blood flow, repair-cell movement, and energy. The BPC-157 + TB-500 pairing is the foundation of the Wolverine Stack; NAD+ keeps the repair work funded.
| Compound | Role |
|---|---|
| BPC-157 | Drives repair at the injury site — builds new blood vessels, activates the cells that lay down new tissue, and makes the injury site more responsive to growth hormone.¹ |
| TB-500 | The migration-side bet. It is the synthetic thymosin beta-4 fragment, not the full parent peptide, and appears to work after metabolic clipping into a shorter repair-active signal. |
| NAD+ | Supplies the cellular energy every repair process runs on. Damaged tissue has compromised mitochondria — NAD+ keeps the energy pipeline open so the other compounds can do their work. |
Oral alternative to BPC-157
PDA — same 15-amino-acid sequence, stabilized with an arginate salt for oral bioavailability.⁸ PDA at 500–1000 mcg/day replaces injectable BPC-157 for readers who want to avoid injections. Trade-off: oral delivery is systemic rather than local, so you lose concentrated signaling near the injury site.
Step 2 — Match Your Injury Type
After establishing the starter stack, add only what matches the bottleneck:
| Injury Type | Add | Rationale |
|---|---|---|
| Connective tissue / collagen quality | GHK-Cu | Regulates collagen turnover and cross-linking — directs repair toward organized functional tissue instead of scar. Add when tissue feels unstable or you keep re-injuring the same site.⁵ |
| Inflammation cycling | KPV | Helps keep the inflammation switch from staying on. Add when swelling returns after activity or the injury keeps oscillating instead of consolidating.³ |
| Disc / spinal degeneration | VIP | Only peptide with direct disc data — slowed degeneration and improved disc cushioning material in a mouse model.⁹ Short half-life (~1 min IV), so frequent dosing matters. |
| Nerve pain / neuropathy | ARA-290 | Activates the innate repair receptor — reduced pain and regenerated small nerve fibers in Phase 2 human trials.¹⁰ Systemic injection, doesn't need to be near the nerve. |
Step 3 — Add Support If Needed
These address bottlenecks that emerge during recovery, not upfront:
| Signal | Add | Why |
|---|---|---|
| Healing stalled after 4+ weeks on core | SS-31 | Stabilizes mitochondrial membranes against oxidative damage that accumulates during prolonged repair.⁴ |
| High stress during recovery | Selank | Reduces anxiety with immune-modulating properties. Breaks the stress → cortisol → impaired healing cycle without sedation. |
| Poor sleep quality | DSIP | Restores deep sleep architecture — the phase where GH-driven repair happens. |
| Weak GH response / slow overnight recovery | Tesamorelin or Sermorelin | Restores pulsatile GH release. Complementary to DSIP — DSIP opens the window, secretagogues amplify the signal. Before bed, empty stomach. Cycle 8–12 weeks on, 4 weeks off. |
For cartilage-specific interest, Cartalax is a short bioregulatory peptide (Ala-Glu-Asp) studied in Russian literature for cartilage matrix preservation — it may slow cartilage breakdown in lab models, but has no injury recovery data and limited availability outside specialty suppliers.²³
Protocol: Dosing, Timing, and Schedules
Core Stack
| Compound | Dose | Route | Timing |
|---|---|---|---|
| BPC-157 | 250–500 mcg | SubQ near injury site | Daily |
| TB-500 | 2–4 mg | SubQ near injury site when safe | 2×/week, then weekly taper if stable |
| NAD+ | 50–250 mg | IM preferred; smaller divided SubQ if needed | About 3×/week |
Inject near the injury site when it is easy and safe. For hard-to-reach locations, abdominal or ordinary SubQ rotation is the practical alternative. BPC-157 and TB-500 can share a syringe on TB-500 days. NAD+ is separate. If KPV is added for tier-2 inflammation cycling, it can share with BPC-157; GHK-Cu should be separate.
These peptides enter systemic circulation rapidly — they don't "stay local." But therapeutic effect is concentration-dependent, and local injection provides a higher first-pass concentration at the injury before dilution.²⁶
TB-500 loading phase
The common field pattern is 2–4 mg twice weekly for 4–8 weeks, often narrowed to 2.5 mg twice weekly for the first block, then weekly taper if stable.¹¹ This is community and equine-derived practice, not a human dose-finding result. The reason small daily microdoses are a weaker fit is practical: TB-500 is used as a short injury-cycle migration signal, and the field signal clusters around pulsed milligram dosing.
Verify whether your product is TB-500 or full-length TB-4 — check the Certificate of Analysis (molecular weight ~859 Da = fragment, ~4,900 Da = full TB-4). The fragment and the parent are related, but not interchangeable. Full-length TB-4 can access pathways the fragment cannot, including Ac-SDKP anti-fibrotic biology. See the TB-500 guide for details.
Calculate your exact injection volumes with the peptide dosing calculator.
Situational Compounds
| Compound | Dose | Route | Timing | Injury Type |
|---|---|---|---|---|
| KPV | 200–500 mcg | SubQ | Daily | Inflammation cycling |
| GHK-Cu | 1–1.5 mg | SubQ | 3×/week | Connective tissue, collagen quality |
| VIP | 100–200 mcg | SubQ | Daily (can split into 2 doses) | Disc, spinal degeneration |
| ARA-290 | 2–4 mg | SubQ, abdomen | Daily | Nerve pain, neuropathy |
Keep GHK-Cu in a separate syringe. ARA-290 is injected systemically — its nerve-protective effects don't require proximity to the nerve injury.¹⁰ VIP's ~1-minute IV half-life means subQ dosing provides brief systemic exposure; splitting the daily dose into two injections extends coverage.
Optional Support Compounds
| Compound | Dose | Route | Timing |
|---|---|---|---|
| SS-31 | 5–10 mg | SubQ | Daily (loading), then 2–3×/week |
| Selank | 250–500 mcg | SubQ or intranasal | Morning or before rehab |
| DSIP | 100–300 mcg | SubQ | Before bed |
| Tesamorelin | 1–2 mg | SubQ | Before bed, empty stomach |
| Sermorelin | 200–500 mcg | SubQ | Before bed, empty stomach |
SS-31
Targets the mitochondria directly — it stabilizes the inner membrane that produces cellular energy (cardiolipin binding⁴). NAD+ provides the fuel; SS-31 protects the engine. Consider it when healing stalls after 4+ weeks on the core stack, suggesting mitochondrial exhaustion that NAD+ alone isn't resolving.⁴
Selank
Can be injected subQ or taken intranasally. Intranasal bypasses liver processing and provides more direct brain access, which may give it an edge for stress and anxiety specifically.
Sleep and GH recovery
DSIP and GH secretagogues (tesamorelin, sermorelin) work on related but distinct problems. DSIP extends the deep sleep window — the phase where GH-driven repair actually happens. Secretagogues amplify the GH signal within that window. They're complementary, not redundant. GH secretagogues are dosed before bed on an empty stomach (90+ minutes after eating) and cycled 8–12 weeks on, 4 weeks off.
Injury-Specific Protocol Adjustments
Tendon, Ligament, and Fascia
The strongest preclinical case for peptide-assisted healing.²¹ BPC-157 promotes tendon repair cell outgrowth and stimulates cell migration (FAK-paxillin signaling¹³). Rat Achilles tendon studies show accelerated healing with improved biomechanical strength.¹ TB-4-treated Achilles tendons showed uniform fiber bundles with increased collagen fibril diameter versus controls.¹⁴
Protocol
Core stack injected near the injury site. Add GHK-Cu if collagen quality is the bottleneck (tissue feels unstable, re-injury at the same site). Collagen peptide supplementation (5–15 g/day, 30–45 min before tendon-loading exercise) is a well-supported adjunct.¹⁵
Plantar fasciitis
No direct peptide data. Plantar fascia is structurally similar to tendon — dense type I collagen, minimal vascularity — and shares the same wear-and-tear degeneration pattern. Same mechanisms are biologically plausible but unvalidated for plantar fascia specifically.
Joint and Cartilage
Joint capsule, ligament, and soft-tissue irritation can use the soft-tissue ladder. Focal cartilage defects are different: cartilage is avascular, slow, and matrix-limited. Those cases route toward a cartilage-specific stack where GHK-Cu is a stronger matrix lever and intra-articular BPC-157 is clinician-only, not an at-home translation. A case series of 17 patients reported symptom reduction in over 90% following intra-articular BPC-157 injections for knee joint conditions.⁷
GH secretagogues and joint injuries: monitor carefully
GH can cause mild joint swelling as a side effect — in joints with existing inflammation, cartilage degradation, or impingement, that additional fluid and tissue growth can worsen symptoms rather than help. If you're adding tesamorelin or sermorelin for overnight recovery, watch for increased joint stiffness or swelling in the first 2 weeks. Discontinue if impingement worsens. Ligament-driven injuries tolerate GH secretagogues better than cartilage or joint surface injuries.
Worth tracking: a 2025 Stanford study showed that blocking the enzyme 15-PGDH in aged mice regenerated articular cartilage — increasing smooth-cartilage-producing cells from 22% to 42%.¹⁶ Small molecule approach, not a peptide, but the most rigorous cartilage regeneration advance in the field. Phase 1 safety trials are underway.
Shoulder and Rotator Cuff
Core stack. BPC-157 at 10 mcg/kg produced total functional recovery in a rat rotator cuff model — full range of motion restored.¹⁷
GH secretagogues for shoulder: negative results
The only human RCT testing GH on rotator cuff repair (Oh 2018, n=76) found no significant improvement.¹⁸ A separate preclinical study found GH actually worsened force-to-failure at the tendon-bone interface.¹⁸ If you're using GH secretagogues for general recovery, monitor for increased shoulder stiffness or impingement — the same joint swelling side effect applies here.
For frozen shoulder, relaxin-2 is mechanistically targeted — it reverses joint capsule scarring in mouse models — but remains preclinical.
Disc, Spine, and Back
For ordinary back strain, fascia, or capsule irritation, use the soft-tissue ladder. Disc, nerve, and CNS presentations route differently. BPC-157 has animal spinal-cord-injury data, but that does not make the soft-tissue stack a CNS protocol.¹⁹ TB-4 reduced nerve cell loss and scar tissue formation in separate models.²⁰
For disc degeneration, add VIP — the only peptide with direct disc data.⁹ For neuropathic pain from nerve compression, add ARA-290.
SS-31 has separate relevance for disc injuries — it reduced inflammation-induced cell death in disc cells by scavenging mitochondrial oxidative stress.¹² For chronic discogenic pain, biomolecular therapies including peptide-based approaches are an active research area, though clinical translation remains early.²⁴
No human RCTs exist for peptides in disc herniation or back pain. The spinal cord injury data involves severe acute trauma models — extrapolation to chronic disc degeneration is mechanistic, not validated. BPC-157 has not been directly tested on herniated discs in any model.
Post-Surgical Recovery
Core stack. Start 48–72 hours post-operatively to allow initial clotting and the acute inflammatory response to settle before introducing repair signaling. BPC-157 injected locally near the surgical site. Phase approach: loading weeks 1–4, maintenance weeks 5–8, extended remodeling weeks 9–12 for complex surgeries.¹¹
BPC-157 can counteract corticosteroid-impaired healing in preclinical models, suggesting compatibility with post-surgical steroid protocols.¹
Chronic and Old Injuries
Core stack plus GHK-Cu, with adjusted expectations. Chronic injuries have established scar tissue, adapted blood supply patterns, and often mitochondrial depletion. Timelines extend to 8–12 weeks versus 4–6 for acute injuries. Add SS-31 if the core stack produces initial improvement that plateaus.
Timeline: What to Expect
| Timeframe | What's Happening |
|---|---|
| Days 1–7 | BPC-157 initiates new blood vessel formation. Injury site may feel warmer as circulation returns. NAD+ supports the energy cost of early repair. |
| Weeks 1–2 | Most people notice reduced pain and improved mobility. TB-500 pulsed dosing supports the migration side of the repair process. |
| Weeks 2–4 | Active tissue remodeling. New collagen deposition begins. Range of motion and load tolerance improve. |
| Weeks 4–8 | Structural maturation. Collagen fibers organize under mechanical load. Physical therapy and progressive loading compound the peptide effects. |
| Weeks 8–12 | Full protocol effects for chronic injuries. Reassess at week 8 — if stalled, evaluate for collagen quality, sleep, or hormonal timing bottlenecks. |
Supporting Factors
Peptides provide biological repair signals. The raw materials for actual tissue construction come from nutrition and mechanical loading.
Collagen peptide supplementation
5–15 g/day, taken 30–45 minutes before tendon-loading exercise or physical therapy. Vitamin C (500–1000 mg, taken with collagen) is a required cofactor for collagen cross-linking. Glycine (3–5 g/day) provides the most abundant amino acid in collagen structure.¹⁵
Progressive mechanical loading
Non-negotiable. Collagen fibers align along lines of mechanical stress. Without controlled loading, new tissue forms as disorganized scar. Peptides and rehab are synergistic — neither replaces the other.
Sleep
GH secretion peaks during deep sleep. DSIP and GH secretagogues address this pharmacologically, but basic sleep hygiene remains the foundation.
FAQ
Protocol Basics
Do I need NAD+ for injury healing?
NAD+ isn't a healing compound — it's the energy currency that fuels every repair process in the protocol. Repair cells, immune cells, and blood vessel cells all require functional mitochondria producing adequate energy. In damaged tissue, mitochondrial function is often compromised by oxidative stress.
Injectable NAD+ at 50–250 mg IM about 3×/week keeps the metabolic pipeline open so BPC-157 and TB-500 can execute their signaling. SubQ is acceptable in smaller divided doses if IM is not workable, but it can sting or welt. Oral precursors (NR or NMN, 250–1000 mg/day) are legitimate for steady support or avoiding injections. You can run the protocol without NAD+ entirely, but you're asking repair cells to work overtime on a depleted energy budget.
What if I only take BPC-157 — can I expect results?
Yes. BPC-157 alone has the strongest individual evidence base for tissue repair among the compounds in this protocol.¹ Many people start with BPC-157 alone and see meaningful improvement, particularly for localized injuries.
The fuller stack addresses more bottlenecks simultaneously — TB-500 adds the migration-side bet, NAD+ covers energy, KPV covers inflammation cycling, and GHK-Cu covers collagen quality — but BPC-157 alone is a reasonable starting point for mild-to-moderate injuries where chronic inflammation isn't the primary issue.
What is the typical cycle length for a BPC-157 + TB-500 injury protocol?
4–8 weeks for acute injuries. 8–12 weeks for chronic conditions.
TB-500 commonly runs 2–4 mg twice weekly for 4–8 weeks, then drops to weekly taper if the tissue is stable. BPC-157 runs daily throughout. Reassess at week 4 (acute) or week 8 (chronic). GH secretagogues cycle separately: 8–12 weeks on, 4 weeks off.
What if healing stalls after 4 weeks?
Reassess using the bottleneck framework. If the starter stack addressed blood flow, migration, and energy, the next question is what is still limiting the tissue: collagen quality — add GHK-Cu; inflammation cycling — add KPV; poor sleep — add DSIP; overnight consolidation failure — consider a GH secretagogue.
If none of the above applies, add SS-31 for mitochondrial membrane instability that NAD+ alone didn't resolve. Don't just extend the same protocol hoping for different results.
Which peptides are best for inflammation?
KPV is the standout. It turns off the inflammation switch (NF-kB³) without the tissue-weakening effects of corticosteroids or the repair-signal suppression of NSAIDs.
BPC-157 has secondary anti-inflammatory properties but isn't primarily an anti-inflammatory compound. For gut-related inflammation, oral KPV acts directly on intestinal tissue via a gut nutrient transporter (PepT1). For injury-specific inflammation, subcutaneous KPV near the injury site provides concentrated local effect.
What if this protocol doesn't work for my specific injury?
First, confirm you're addressing the right bottleneck. The most common reason protocols underperform isn't the wrong compounds — it's the wrong diagnosis of what's stalling healing.
Second, check the non-peptide fundamentals: progressive mechanical loading, collagen supplementation, sleep quality, nutrition. Their absence limits the protocol's effectiveness.
Third, if the core stack produced initial improvement that plateaued, that's a specific signal: consider SS-31 for mitochondrial support or GHK-Cu for collagen remodeling. If nothing has moved after 4 weeks with proper rehabilitation, consult a physician — the injury may require imaging or intervention that peptides can't replace.
Safety and Regulatory
Are any of these peptides FDA approved?
No. None of the peptides in this protocol have FDA approval for injury recovery.
BPC-157, TB-500, and KPV have unsettled compounding-pathway status after FDA removed them from Category 2 in April 2026 and scheduled PCAC review. That affects access and compounding; it is not the same as approval for injury recovery. SS-31 (elamipretide) is FDA-approved as Forzinity for Barth syndrome, but that label does not translate into injury-recovery approval. ARA-290 completed Phase 2 trials for sarcoidosis neuropathy but development stalled.
The absence of FDA approval reflects patent economics. BPC-157 is a fragment of a naturally occurring gastric protein — it cannot be patented as a novel compound, which means no company can recoup the $1–2 billion cost of full approval. The same economic barrier applies to most peptides derived from endogenous human sequences. Regulatory status tells you about commercial viability, not about safety or efficacy.
Is BPC-157 safe? Is TB-500 safe? Are there side effects?
BPC-157: No acute toxicity across a wide dose range in 6-week animal studies.¹ Side effects are mild — occasional injection-site irritation, GI upset with oral dosing. No long-term studies beyond 6 weeks exist.
TB-500/TB-4: Phase I human safety data exists for recombinant TB-4 — 84 healthy volunteers (54 single-dose, 30 multiple-dose) tolerated doses up to 25 μg/kg daily for 10 days with no serious adverse events.²⁵ The synthetic TB-500 and TB-4 sold by peptide suppliers differ from the recombinant version used in this trial, and their safety profiles have not been independently characterized.
KPV: Tripeptide fragment of alpha-MSH, a naturally occurring hormone. No adverse events in published research, but no formal human safety studies exist either.
Short-term data is reassuring but not comprehensive.
Do BPC-157 and TB-500 cause cancer?
No evidence of tumor promotion exists for either compound.
BPC-157's blood-vessel-forming properties raise a theoretical concern — tumors need blood supply, and a compound that promotes capillary formation could theoretically support that. However, preclinical data suggests BPC-157 may actually inhibit certain tumor growth pathways.²² TB-4 research has found both pro- and anti-tumorigenic associations in different tissue contexts.
Anyone with active cancer or recent cancer history should avoid blood-vessel-forming compounds as a precaution. For people without cancer history, the theoretical risk appears low, but long-term human studies that would definitively resolve this don't exist.
Can I take BPC-157, TB-500, and KPV with NSAIDs or ibuprofen?
You can, but it may blunt the protocol's effectiveness. NSAIDs suppress inflammatory signaling that BPC-157 and TB-500 modulate as part of the repair process. Suppressing inflammation pharmacologically while trying to support it with peptides creates competing signals.
KPV works differently — it turns off the inflammation switch (NF-kB) to resolve chronic inflammation without suppressing repair signals. Running KPV alongside NSAIDs is less contradictory, but redundant.
If you need pain management during the protocol, use NSAIDs sparingly at the lowest effective dose rather than daily. Corticosteroids present a stronger concern — they directly impair collagen quality.
What are the contraindications?
Active cancer or history of cancer — BPC-157's blood-vessel-forming properties are theoretically concerning for tumor blood supply. No evidence of tumor promotion exists, and preclinical data suggests BPC-157 may inhibit certain tumor growth pathways,²² but the theoretical concern warrants caution.
Pregnancy and lactation — insufficient safety data. Autoimmune conditions — immune-modulating peptides (KPV, TB-500, Selank) may alter immune balance unpredictably.
Pharmacokinetics
How long do BPC-157 and TB-500 remain in your system?
BPC-157 clears in approximately 15 minutes (IV/IM studies in rats and dogs — no formal human subQ data exists). But plasma clearance doesn't equal effect duration. BPC-157 triggers gene expression cascades that persist for weeks to months after the compound clears.¹⁹ The peptide delivers instructions; the biological response continues independently.
TB-4 has the better human data: Phase I studies in 84 healthy volunteers showed a dose-dependent half-life of 0.5–2.1 hours after IV administration.²⁵ Caveat: these studies used recombinant human thymosin beta-4, not the synthetic TB-500 fragment or synthetic TB-4 via subQ — the pharmacokinetics may differ.
How long do KPV and VIP remain in your system?
KPV has no published half-life data in any species. As an unmodified tripeptide, it likely clears within minutes. Anti-inflammatory effects persist longer because the inflammation switch (NF-kB) stays off after the peptide clears.
VIP has well-established human pharmacokinetics: approximately 1-minute half-life after IV administration. SubQ absorption is slower than IV, which provides somewhat longer exposure per dose. Splitting the daily dose into two injections extends coverage further. The disc degeneration research used local delivery models, but community protocols use systemic subQ at 100–200 mcg/day.⁹
How long do NAD+ and SS-31 remain in your system?
Injectable NAD+ supports the metabolic pool through extracellular breakdown into usable precursors plus acute signaling. IM is the preferred at-home route for active rebuilds; SubQ can work at smaller divided doses but often stings more. Oral precursors (NMN, NR) are legitimate steady-support options rather than fake substitutes.
SS-31 (elamipretide) has the best pharmacokinetic data of any compound in this protocol — Phase I through III human trials. SubQ: peak plasma in 1–2 hours, half-life approximately 4 hours. Unusually long for a peptide because SS-31 contains unnatural amino acids that resist enzymatic breakdown.
How long does ARA-290 remain in your system?
Approximately 20 minutes half-life after subQ injection (human data from multiple clinical trials). Despite the short plasma presence, biological effects persist far longer — activation of the innate repair receptor triggers downstream gene expression lasting hours. This is why dosing is once daily despite 20-minute clearance.¹⁰
Administration
Where to inject BPC-157, TB-500, and KPV
Yes — near the injury site when possible. For hard-to-reach locations (spine, deep hip), abdominal injection is the practical alternative.
The peptides don't "stay local" — they enter systemic circulation rapidly. But therapeutic effect is concentration-dependent, and local injection provides a higher first-pass concentration at the injury before dilution.²⁶
BPC-157, TB-500, and KPV are chemically compatible — draw all three into the same syringe on TB-500 days if KPV is part of the protocol. On non-TB-500 days, BPC-157 + KPV can share one injection. GHK-Cu and NAD+ stay separate.
Where do I inject ARA-290? Where do I inject VIP?
ARA-290: subcutaneous, typically abdominal. The sarcoidosis neuropathy trials used systemic delivery, not local injection. Its neuroprotective effects don't require proximity to the nerve injury.¹⁰
VIP: subcutaneous, 100–200 mcg daily. The ~1-minute IV half-life is short, so splitting into two doses (morning and evening) extends coverage. SubQ absorption is slower than IV, which helps. The disc degeneration research used local delivery models, but community protocols use systemic subQ.
SS-31 is expensive — what role does it play and is it worth it?
SS-31 protects mitochondrial membranes. NAD+ provides the fuel; SS-31 protects the machinery that burns it.⁴
It's not a first-line compound. Consider it only if healing stalls after 4+ weeks on the core stack — that suggests mitochondrial exhaustion that NAD+ alone isn't resolving. For chronic injuries with long-standing tissue damage, the case is stronger from the start.
For a mild acute injury responding to the core stack, SS-31 is unnecessary. For a chronic injury that has resisted other interventions, it addresses a bottleneck that nothing else in the protocol targets.
Is there a difference between oral BPC-157 (PDA) and the injectable version?
Same 15-amino-acid sequence, different delivery. PDA stabilizes BPC-157 with an arginate salt for oral bioavailability.⁸ Injectable near the injury site concentrates the compound locally. Oral PDA distributes systemically — lower concentration at any specific site, broader coverage overall.
For localized injuries, injectable is preferred. For systemic inflammation, gut healing, or avoiding injections entirely, oral PDA at 500–1000 mcg/day is the alternative. Some practitioners use both.
Is there a difference between oral and injectable KPV?
Yes. Oral KPV reaches intestinal tissue directly via a gut nutrient transporter (PepT1) — specifically effective for gut inflammation. Injectable KPV (subQ) provides systemic anti-inflammatory coverage including at injury sites.
For injury-specific inflammation, subcutaneous KPV is the default. Oral KPV is mainly a gut-local tool and makes the most sense when the formulation is protected, enteric, or carrier-style.
Does it matter if I use a nasal spray or injection for Selank?
Both work. SubQ injection is the default in this protocol since you're already injecting. Intranasal bypasses liver processing and provides more direct brain access, which is where Selank's anxiety-reducing effects are most relevant — so intranasal may have an edge for stress and anxiety specifically.
Compatibility
Can I use this protocol alongside GLP-1 based weight-loss therapy?
No direct interaction data exists. They target entirely different receptor systems.
The practical concern is metabolic context. GLP-1 therapy produces significant caloric deficit and muscle mass reduction. Tissue repair is metabolically expensive. Running an aggressive recovery protocol during aggressive caloric restriction may limit healing capacity.
If you're on GLP-1 therapy during injury recovery: prioritize protein intake (1.6–2.2 g/kg/day minimum), collagen peptide supplementation, and ensure your caloric deficit isn't starving the repair process.
Can I use peptides alongside physical therapy?
Not only can you — you should. Peptides provide biological repair signals. Physical therapy provides mechanical loading signals. Collagen fibers align along lines of stress; without controlled loading, new tissue forms as disorganized scar.
The combination is synergistic — neither replaces the other. Time collagen peptide supplementation (5–15 g with vitamin C) 30–45 minutes before PT sessions.¹⁵
What additional benefits might I notice from this protocol?
The compounds don't limit their effects to one injury site. Practitioners commonly report improved skin quality, faster healing at unrelated sites, and reduced GI symptoms as secondary effects of BPC-157.¹ GHK-Cu improves skin elasticity and wound healing beyond the target injury.⁵ NAD+ has broad metabolic effects beyond the injury site.
Injury-Specific
What should I add for a tendon or ligament injury?
Core stack with BPC-157 injected locally. This is the strongest preclinical case: BPC-157 promotes tendon repair cell outgrowth,¹³ TB-4 increases collagen fibril diameter and fiber organization in Achilles tendon models.¹⁴ Add GHK-Cu if tissue feels unstable or you're re-injuring at the same site. Supplement with collagen peptides 30–45 minutes before tendon-loading exercise.¹⁵
What about joint and cartilage injuries?
Joint capsule, ligament, and soft-tissue irritation can use the soft-tissue ladder. Focal cartilage defects are different: cartilage is avascular, slow, and matrix-limited. Those cases route toward a cartilage-specific stack; intra-articular BPC-157 is clinician-only, not an at-home conversion. A 17-patient case series reported symptom reduction in over 90% following intra-articular BPC-157 for knee conditions.⁷
GH secretagogues can cause mild joint swelling — monitor carefully if adding them alongside a joint injury. Discontinue if impingement or stiffness worsens. Ligament-driven injuries tolerate them better than cartilage or joint surface problems.
What should I add for a shoulder or rotator cuff injury?
Core stack. BPC-157 produced total functional recovery in a rat rotator cuff model.¹⁷
Be cautious with GH secretagogues. The only human RCT testing GH on rotator cuff repair (n=76) found no significant improvement, and a separate preclinical study found GH actually worsened tendon-bone interface strength.¹⁸ If using them for general recovery support, watch for increased shoulder stiffness or swelling.
What should I add for disc, spine, or back pain?
For ordinary back strain, fascia, or capsule irritation, use the soft-tissue ladder. Disc, nerve, and CNS presentations route differently. For disc degeneration, VIP is the only peptide with direct disc data.⁹ For nerve pain from compression, add ARA-290.¹⁰ BPC-157 has animal spinal-cord-injury data, but that does not make the soft-tissue stack a CNS protocol.¹⁹
No human RCTs exist for peptides in disc herniation or back pain. The evidence gap between animal spinal cord data and human disc pathology is real.
What about post-surgical recovery?
Core stack, started 48–72 hours post-op. BPC-157 injected locally near the surgical site. Loading weeks 1–4, maintenance weeks 5–8, extended remodeling weeks 9–12 for complex surgeries.¹¹
BPC-157 can counteract corticosteroid-impaired healing in preclinical models — relevant if your post-surgical protocol includes steroids.¹
What about chronic or old injuries?
Core stack plus GHK-Cu or KPV when the bottleneck calls for it, with adjusted expectations. Timelines extend to 8–12 weeks. Chronic injuries have established scar tissue, adapted blood supply patterns, and often mitochondrial depletion.
Add SS-31 if the core stack produces initial improvement that plateaus. These injuries also respond more to progressive mechanical loading — the tissue remodels along lines of mechanical stress, and progressive loading provides those stress signals.
References
¹ Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS J. 2025 Jul. PMC12313605
² Sosne G et al. "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts." FASEB J. 2010. PubMed 20536458
³ Dalmasso G et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008. PMC2431115 — KPV enters cells via PepT1 transporter and blocks NF-kB activation directly; anti-inflammatory without the tissue-weakening effects of corticosteroids.
⁴ Birk AV et al. "The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." J Am Soc Nephrol. 2013. PMC3752943 — SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport and ATP production under stress.
⁵ Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018. PMC6073405
⁶ Rahman OF, Lee SJ, Seeds WA. "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMC12753158
⁷ Rahman OF et al. 2026 — combined administration data, GHK-Cu orthopaedic exploration, GH secretagogue evidence, BPC-157 case series (n=17). PMC12753158
⁸ PDA retains the identical 15-amino-acid sequence as BPC-157, enhanced with arginate salt for increased acid stability and oral bioavailability. Rahman OF et al. 2026. PMC12753158 — Also referenced in ScienceDirect "Application of peptide therapy for ligaments and tendons," 2025 (incomplete citation — no DOI or PMID available for the ScienceDirect source).
⁹ Sun et al. "Sympathetic Neurotransmitter, VIP, Delays Intervertebral Disc Degeneration via FGF18/FGFR2." 2023/2024. Note: the link below is a press summary from Advanced Science News, not the primary publication. Press summary
¹⁰ Heij L et al. "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study." Mol Med. 2012. PMC3521784 — ARA-290 activates the innate repair receptor; neuroprotective and small-fiber regenerative without erythropoietic effects.
¹¹ Practitioner-derived protocol convention — TB-500 pulsed milligram dosing, BPC-157 daily signaling-pulse model, phase-based dosing structure. Sources: wolverinepeptidestack.com protocols; Ben Greenfield "Ultimate Peptide Power Plays." Note: these are practitioner observations, not primary research. No controlled studies have compared TB-500 loading vs. daily microdosing regimens.
¹² SS-31 attenuated LPS-induced apoptosis and pyroptosis of nucleus pulposus cells via mitochondrial ROS scavenging. ScienceDirect 2024.
¹³ Chang et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011. PubMed 21030672
¹⁴ TB-4 tendon organization — Sosne G et al. 2010 — thymosin beta-4 treated Achilles tendons showed uniform fiber bundles with increased collagen fibril diameters vs controls. PubMed 20536458
¹⁵ Kirmani BH et al. "The effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: a systematic review." Amino Acids. 2021. PMC8521576 — and Kvist M et al. 2025 (collagen + explosive strength RCT). PubMed 40623147
¹⁶ Singla M, Wang YX et al. "Blocking a master regulator of aging regenerates joint cartilage in mice." Science, Nov 2025. Stanford News
¹⁷ Sikiric et al. "Effect of pentadecapeptide BPC 157 on rotator cuff tear injury in rat." FASEB J. 2014;28(S1):844.9. FASEB
¹⁸ Oh et al. "Effect of recombinant human growth hormone on rotator cuff healing after arthroscopic repair." Am J Sports Med. 2018. PubMed 29337026 — and Vaysman et al. "Pharmacologic Enhancement of Rotator Cuff Repair: A Narrative Review." PMC9441107
¹⁹ Jurjus et al. "BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats." J Appl Biomed. 2019. PubMed 31266512
²⁰ TB-4 spinal cord injury — "Beneficial effects of thymosin beta4 on spinal cord injury in the rat." 2014. PubMed 24937047
²¹ Cushman CJ et al. "Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review." Yale J Biol Med. 2024;97(3):399-413. PMC11426299
²² McGuire FP et al. "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing." Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC12446177
²³ Liao HJ, Chen HT, Chang CH. "Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis." Cartilage. 2024. PMC11556548
²⁴ Rudnik-Jansen et al. "Biomolecular therapies for chronic discogenic low back pain: A narrative review." 2024. PMC11303450
²⁵ Wang et al. "Phase I study of recombinant human thymosin β4." Ann Transl Med. 2021. PMC8419156
²⁶ Local concentration matters for therapeutic effect — Free systemic TB-4 at the same total dose as a fibrin-targeted nanoparticle formulation produced no functional improvement in cardiac repair — systemic dilution dropped tissue concentration below therapeutic threshold. Huang G et al. "Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles." Int J Nanomedicine. 2017;12:3023-3036. PMC5396927
This content is for educational purposes only. Peptides discussed here are investigational compounds. Consult a physician before beginning any peptide protocol, particularly if you have active cancer, autoimmune conditions, or are taking medications that affect immune function or coagulation.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.